Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.134
Filter
1.
J Hazard Mater ; 478: 135526, 2024 Oct 05.
Article in English | MEDLINE | ID: mdl-39153300

ABSTRACT

Phenol and p-cresol are two common toxic small molecules related to various diseases. Existing reports confirmed that high L-tyrosine in the daily diet can increase the concentration of phenolic compounds in blood and urine. L-tyrosine is a common component of protein-rich foods. Some anaerobic bacteria in the gut can convert non-toxic l-tyrosine into these two toxic phenolic compounds, phenol and p-cresol. Existing methods have been constructed for measuring the concentration of phenolic compound in feces. However, there is still a lack of direct visual evidence to measure the phenolic compounds in the intestine. In this study, we aimed to construct a whole-cell biosensor for phenolic compounds detection based on the dmpR, the regulator from the phenol metabolism cluster. The commensal bacterium Citrobacter amalonaticus PS01 was selected and used as the chassis. Compared with the biosensor based on ECN1917, the biosensor PS01[dmpR] could better implant into the mouse gut through gavage and showed a higher sensitive to phenolic compound. And the concentration of phenolic compounds in the intestines could be observed with the help of in vivo imaging system using PS01[dmpR]. This paper demonstrated endogenous phenol synthesis in the gut and the strategy of using commensal bacteria to construct whole-cell biosensors for detecting small molecule compounds in the intestines.


Subject(s)
Biosensing Techniques , Intestines , Animals , Citrobacter/metabolism , Cresols/metabolism , Cresols/toxicity , Phenols/toxicity , Mice , Phenol/analysis , Phenol/toxicity , Tyrosine/metabolism
2.
Zoological Lett ; 10(1): 14, 2024 Aug 01.
Article in English | MEDLINE | ID: mdl-39090696

ABSTRACT

In addition to the type locality (the summit of Aprada-tepui, Bolívar State of Venezuela), the distribution of the egg-brooding frog Stefania satelles was long thought to include several isolated tabletop mountain (tepui) summits surrounding the large Chimantá Massif in Bolívar State (hence the Latin name "satelles"). However, multilocus molecular phylogenetic analyses have revealed that this taxon includes several undescribed morphologically cryptic species, and that S. satelles should be restricted to its type locality. Two tepui-summit species confused under that name in the literature remain to be named, and the present paper aims at describing these populations previously referred to as Stefania sp. 3 and S. sp. 5. Stefania sp. 3 is only known from the small summit of Angasima-tepui, while S. sp. 5 is only reported from the small summit of Upuigma-tepui, both mountains being located south of the Chimantá Massif. These new, phylogenetically distinct species are described based on external morphology and osteology and in comparison to close relatives in the S. ginesi clade, which consists exclusively of tepui summit species. Both new species have highly restricted geographic ranges (less than 3 km2) and should be listed as Critically Endangered according to IUCN criteria.

3.
BMC Infect Dis ; 24(1): 843, 2024 Aug 20.
Article in English | MEDLINE | ID: mdl-39164620

ABSTRACT

BACKGROUND: Rapid point-of-care tests for malaria are now widely used in many countries to guide the initial clinical management of patients presenting with febrile illness. With China having recently achieved malaria elimination, better understanding regarding the identity and distribution of major non-malarial causes of febrile illnesses is of particular importance to inform evidence-based empirical treatment policy. METHODS: A systematic review of published literature was undertaken to characterise the spectrum of pathogens causing non-malaria febrile illness in China (1980-2015). Literature searches were conducted in English and Chinese languages in six databases: Ovid MEDLINE, Global Health, EMBASE, Web of Science™ - Chinese Science Citation Database SM, The China National Knowledge Infrastructure (CNKI), and WanFang Med Online. Selection criteria included reporting on an infection or infections with a confirmed diagnosis, defined as pathogens detected in or cultured from samples from normally sterile sites, or serological evidence of current or past infection. The number of published articles, reporting a given pathogen were presented, rather than incidence or prevalence of infection. RESULTS: A total of 57,181 records from 13 provinces of China where malaria used to be endemic were screened, of which 392 met selection criteria and were included in this review. The review includes 60 (15.3%) records published from 1980 to 2000, 211 (53.8%) from 2001 to 2010 and 121 (30.9%) from 2011 to 2015;. Of the 392 records, 166 (42.3%) were from the eastern region of China, 120 (30.6%) were from the south-west, 102 (26.0%) from south-central, and four (1.0%) were multi-regional studies. Bacterial infections were reported in 154 (39.3%) records, viral infections in 219 (55.9%), parasitic infections in four (1.0%), fungal infections in one (0.3%), and 14 (3.6%) publications reported more than one pathogen group. Participants of all ages were included in 136 (34.7%) studies, only adults in 75 (19.1%), only children in 17 (4.3%), only neonates in two (0.5%) and the age distribution was not specified in 162 (41.3%) records. The most commonly reported bacterial pathogens included Typhoidal Salmonella (n = 30), Orientia/ Rickettsia tsutsugamushi (n = 31), Coxiella burnetii (n = 17), Leptospira spp. (n = 15) and Brucella spp. (n = 15). The most commonly reported viral pathogens included Hantavirus/Hantaan virus (n = 89), dengue virus (DENV) (n = 76 including those with unknown serovars), Japanese encephalitis virus (n = 21), and measles virus (n = 15). The relative lack of data in the western region of the country, as well as in in neonates and children, represented major gaps in the understanding of the aetiology of fever in China. CONCLUSIONS: This review presents a landscape of non-malaria pathogens causing febrile illness in China over 36 years as the country progressed toward malaria elimination. These findings can inform guidelines for clinical management of fever cases and infection surveillance and prevention, and highlight the need to standardize operational and reporting protocols for better understanding of fever aetiology in the country.


Subject(s)
Fever , Humans , China/epidemiology , Fever/epidemiology , Fever/etiology , Malaria/epidemiology
4.
Microbiol Spectr ; : e0097424, 2024 Aug 20.
Article in English | MEDLINE | ID: mdl-39162536

ABSTRACT

Timely and accurate identification of yeasts is essential for adequate treatment, considering the increase in antifungal resistance of some species, particularly for C. auris. Current matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) manufacturer's protocol for identification of yeasts requires 24- to 72-h cultivation on Sabouraud dextrose media (SAB), but not some of the mainstay primary culture media used in mycology such as inhibitory mold agar (IMA), Mycosel, CHROMagar Candida Plus, and CHROMagar Candida. As culture media can influence MALDI-TOF MS identification results, this study evaluated the accuracy and performance of identification of clinically relevant yeasts on these first-line media using the VITEK-MS MALDI-TOF MS system.IMPORTANCEIn this study, a panel of 140 strains (21 species) was used to assess the performance of the selected media. Although not in the manufacturer's list of accepted media, IMA and chromogenic media are suitable for the identification of yeasts on the VITEK-MS systems. CHROMagar Candida Plus allowed the identification of 135/140 isolates tested after 24-h incubation similar to SAB reference media (137/140). Yeast isolates that grew on Mycosel selective media were also reliably identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. VITEK-MS system with IVD database V3.2 correctly identified C. auris strains to the species level on CHROMagar Candida Plus alleviating the need for subcultivation and reduced turnaround time (24-72 h) to identification for patient screening.

5.
Phys Rev Lett ; 133(7): 076302, 2024 Aug 16.
Article in English | MEDLINE | ID: mdl-39213570

ABSTRACT

We demonstrate an efficient and continuous microwave photon-to-electron converter with large quantum efficiency (83%) and low dark current. These unique properties are enabled by the use of a high kinetic inductance disordered superconductor, granular aluminium, to enhance light-matter interaction and the coupling of microwave photons to electron tunneling processes. As a consequence of strong coupling, we observe both linear and nonlinear photon-assisted processes where two, three, and four photons are converted into a single electron at unprecedentedly low light intensities. Theoretical predictions, which require quantization of the photonic field within a quantum master equation framework, reproduce well the experimental data. This experimental advancement brings the foundation for high-efficiency detection of individual microwave photons using charge-based detection techniques.

6.
Article in English | MEDLINE | ID: mdl-38984693

ABSTRACT

AIMS: To evaluate the prognostic implications of left atrial reservoir strain-defined diastolic dysfunction (LARS-DD) grade in patients undergoing TAVI for severe aortic stenosis (AS) and to determine if post-TAVI LARS was more closely associated with new-onset atrial fibrillation than pre-TAVI LARS. METHODS AND RESULTS: Pre-TAVI LARS-DD was evaluated by speckle-tracking echocardiography and was assigned as grade 0 to 1 (LARS≥24%), grade 2 (LARS≥19 to <24%) and grade 3 (LARS<19%). Patients were followed-up for the primary endpoint of all-cause mortality from the date of TAVI. For the secondary endpoint, patients with pre- and post-TAVI LARS measurements and no history of atrial fibrillation were evaluated for the occurrence of new-onset atrial fibrillation. A total of 601 patients (median age 81 [76-85] years, 53% male) were included. Overall, 169 patients (28%) were LARS-DD grade 0/1, 96 patients (16%) were LARS-DD grade 2 and 336 (56%) were LARS-DD grade 3. Over a median follow-up of 40 (IQR 26-58) months, a total of 258 (43%) patients died. In a comprehensive multivariable Cox regression model, LARS-DD grade was independently associated with all-cause mortality (adjusted HR 1.28 per one-grade increase, 95%CI 1.07-1.53, P=0.007). For the secondary endpoint of new-onset atrial fibrillation, a total of 285 patients were evaluated. Post-TAVI LARS (SDHR 1.14 per 1%<20%, 95%CI 1.05-1.23, P=0.0009), but not pre-TAVI LARS (P=0.93) was independently associated with new-onset atrial fibrillation. CONCLUSIONS: Increasing LARS-DD grade was independently associated with long-term post-TAVI survival in patients with severe AS. Post-TAVI LARS was closely related to the occurrence of new-onset atrial fibrillation.

7.
Eur Urol Open Sci ; 66: 12-15, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39027656

ABSTRACT

Neuropeptide Y (NPY) and related peptides have been proposed as promising biomarkers for the diagnosis of prostate cancer by previous immunoassays and immunohistochemical studies. In this study, we evaluated the additional value of NPY and related peptides compared with prostate-specific antigen (PSA). We performed a comprehensive analysis of NPY, its precursors, and metabolite concentrations in both plasma and tissue samples from 181 patients using a highly specific liquid chromatography tandem mass spectrometry method. Compared with PSA, NPY and related peptides (NPYs) were less accurate at diagnosing significant prostate cancer. Combinations of NPYs in a stepwise approach did not improve a model that would be beneficial for patients. NPY may be beneficial for patients presenting with a PSA concentration in the gray area between 4 and 9 ng/ml, but the strength of this conclusion is limited. Thus, the use of NPYs as standalone or in combination with other variables, such as PSA, prostate volume, or age, to improve the diagnosis is not supported by our study. Patient summary: This study evaluated neuropeptide Y (NPY) of the family of endogenous peptides as a new biomarker to diagnose prostate cancer. We found that NPY in a patient's blood was not more helpful at diagnosing prostate cancer than the standard prostate-specific antigen blood test. Further research is needed to explore the potential of NPY and related peptides in specific subgroups of patients.

8.
Am J Trop Med Hyg ; 111(2): 365-376, 2024 Aug 07.
Article in English | MEDLINE | ID: mdl-38955166

ABSTRACT

A systematic review (SR) of published efficacy studies in visceral leishmaniasis (VL) was undertaken to describe methodological aspects of design, conduct, analysis, and reporting. Studies published during 2000-2021 and indexed in the Infectious Diseases Data Observatory VL library of clinical studies were eligible for inclusion (N = 89 studies). Of the 89 studies, 40 (44.9%) were randomized, 33 (37.1%) were single-armed, 14 (15.7%) were nonrandomized multiarmed studies, and randomization status was unclear in two (2.2%). After initial screening, disease confirmation was done by microscopy in 26 (29.2%) and by a combination of serology and microscopy in 63 (70.8%). Post-treatment follow-up duration was <6 months in three (3.3%) studies, 6 months in 75 (84.3%), and >6 months in 11 (12.4%) studies. Confirmation of relapse was solely based on clinical suspicion in four (4.5%) studies, parasitological demonstration in 64 (71.9%), using molecular/serological/parasitological method in 6 (6.7%), and there was no information in 15 (16.9%). Of the 40 randomized studies, sample size calculation was reported in only 22 (55.0%) studies. This review highlights substantial variations in definitions adopted for disease diagnosis and therapeutic outcomes suggesting a need for a harmonized trials protocol.


Subject(s)
Antiprotozoal Agents , Leishmaniasis, Visceral , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/epidemiology , Humans , Antiprotozoal Agents/therapeutic use , Research Design , Treatment Outcome , Randomized Controlled Trials as Topic
9.
Rev Cardiovasc Med ; 25(1): 29, 2024 Jan.
Article in English | MEDLINE | ID: mdl-39077670

ABSTRACT

Multivalvular heart disease (MVD) implies the presence of concomitant valvular lesions on two or more heart valves. This condition has become common in the few last years, mostly due to population aging. Every combination of valvular lesions uniquely redefines the hemodynamics of a patient. Over time, this may lead to alterations in left ventricle (LV) dimensions, shape and, eventually, function. Since most of the echocardiographic parameters routinely used in the valvular assessment have been developed in the context of single valve disease and are frequently flow- and load-dependent, their indiscriminate use in the context of MVD can potentially lead to errors in judging lesion severity. Moreover, the combination of non-severe lesions may still cause severe hemodynamic consequences, and thereby systolic dysfunction. This review aims to discuss the most frequent combinations of MVD and their echocardiographic caveats, while addressing the opportunities for a multimodality assessment to achieve a better understanding and treatment of these patients.

10.
Res Q Exerc Sport ; : 1-9, 2024 May 22.
Article in English | MEDLINE | ID: mdl-38776467

ABSTRACT

Purpose: Coordination in ice hockey skating has been minimally investigated, particularly in females. The objective was to compare lower-extremity inter-segment coordination of collegiate male and female ice hockey players during forward skating starts. Methods: 3D kinematic data were collected on collegiate male (n = 9) and female (n = 10) participants during accelerative steps. Continuous relative phase (CRP) was calculated for shank-sagittal/thigh-sagittal, shank-sagittal/thigh-frontal, and foot-sagittal/shank-sagittal segment pairs across 2.5 strides on each side. Principal component analysis (PCA) extracted features of greatest variability of the CRP and relationships between principal components and sex were investigated using hierarchical linear model. Results: Males demonstrated more out-of-phase coordination (higher CRP) for side one (p = .01) and side two (p < .01) shank-sagittal/thigh-sagittal as well as side one shank-sagittal/thigh-frontal (p < .01) segment pairs throughout each step. Females demonstrated a greater change in CRP from late stance/early swing to late swing/early stance on side two for shank-sagittal/thigh-frontal segments (p < .01). For side two shank-sagittal/thigh-frontal segments, faster males utilized more out-of-phase coordination throughout each step whereas faster females utilized more in-phase coordination (p < .01). Conclusion: Males and females may employ different coordinative strategies to achieve faster skating speeds. Males tend to utilize more out-of-phase coordination of the shank and thigh throughout strides, although coordinative differences of the shank and foot were not found between sexes. Further investigation is needed to examine the relationship between lower limb strength and coordination as well as the effect of targeted training protocols on lower extremity coordinative patterns.

11.
Trans R Soc Trop Med Hyg ; 118(8): 481-490, 2024 Aug 05.
Article in English | MEDLINE | ID: mdl-38690667

ABSTRACT

Blood transfusion remains an important aspect of patient management in visceral leishmaniasis (VL). However, transfusion triggers considered are poorly understood. This review summarises the transfusion practices adopted in VL efficacy studies using the Infectious Diseases Data Observatory VL clinical trials library. Of the 160 studies (1980-2021) indexed in the IDDO VL library, description of blood transfusion was presented in 16 (10.0%) (n=3459 patients) studies. Transfusion was initiated solely based on haemoglobin (Hb) measurement in nine studies, combining Hb measurement with an additional condition (epistaxis/poor health/clinical instability) in three studies and the criteria was not mentioned in four studies. The Hb threshold range for triggering transfusion was 3-8 g/dL. The number of patients receiving transfusion was explicitly reported in 10 studies (2421 patients enrolled, 217 underwent transfusion). The median proportion of patients who received transfusion in a study was 8.0% (Interquartile range: 4.7% to 47.2%; range: 0-100%; n=10 studies). Of the 217 patients requiring transfusion, 58 occurred before VL treatment initiation, 46 during the treatment/follow-up phase and the time was not mentioned in 113. This review describes the variation in clinical practice and is an important initial step in policy/guideline development, where both the patient's Hb concentration and clinical status must be considered.


Subject(s)
Blood Transfusion , Leishmaniasis, Visceral , Leishmaniasis, Visceral/therapy , Humans , Antiprotozoal Agents/therapeutic use , Hemoglobins/analysis , Treatment Outcome
12.
Eur Heart J ; 45(20): 1831-1839, 2024 May 27.
Article in English | MEDLINE | ID: mdl-38740526

ABSTRACT

BACKGROUND AND AIMS: Arrhythmic mitral valve prolapse (AMVP) is linked to life-threatening ventricular arrhythmias (VAs), and young women are considered at high risk. Cases of AMVP in women with malignant VA during pregnancy have emerged, but the arrhythmic risk during pregnancy is unknown. The authors aimed to describe features of women with high-risk AMVP who developed malignant VA during the perinatal period and to assess if pregnancy and the postpartum period were associated with a higher risk of malignant VA. METHODS: This retrospective international multi-centre case series included high-risk women with AMVP who experienced malignant VA and at least one pregnancy. Malignant VA included ventricular fibrillation, sustained ventricular tachycardia, or appropriate shock from an implantable cardioverter defibrillator. The authors compared the incidence of malignant VA in non-pregnant periods and perinatal period; the latter defined as occurring during pregnancy and within 6 months after delivery. RESULTS: The authors included 18 women with AMVP from 11 centres. During 7.5 (interquartile range 5.8-16.6) years of follow-up, 37 malignant VAs occurred, of which 18 were pregnancy related occurring in 13 (72%) unique patients. Pregnancy and 6 months after delivery showed increased incidence rate of malignant VA compared to the non-pregnancy period (univariate incidence rate ratio 2.66, 95% confidence interval 1.23-5.76). CONCLUSIONS: The perinatal period could impose increased risk of malignant VA in women with high-risk AMVP. The data may provide general guidance for pre-conception counselling and for nuanced shared decision-making between patients and clinicians.


Subject(s)
Mitral Valve Prolapse , Pregnancy Complications, Cardiovascular , Humans , Female , Pregnancy , Mitral Valve Prolapse/complications , Mitral Valve Prolapse/epidemiology , Retrospective Studies , Adult , Pregnancy Complications, Cardiovascular/epidemiology , Risk Factors , Arrhythmias, Cardiac/epidemiology , Arrhythmias, Cardiac/etiology , Tachycardia, Ventricular/epidemiology , Tachycardia, Ventricular/etiology , Puerperal Disorders/epidemiology , Puerperal Disorders/etiology , Defibrillators, Implantable , Incidence , Ventricular Fibrillation/epidemiology , Ventricular Fibrillation/etiology , Postpartum Period
13.
PLoS Negl Trop Dis ; 18(4): e0011635, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38626228

ABSTRACT

BACKGROUND: Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis which can occur after successful treatment of visceral leishmaniasis (VL) and is a public health problem in VL endemic areas. We conducted a systematic scoping review to assess the characteristics of published PKDL clinical studies, understand the scope of research and explore the feasibility and value of developing a PKDL individual patient data (IPD) platform. METHODS: A systematic review of published literature was conducted to identify PKDL clinical studies by searching the following databases: PubMed, Scopus, Ovid Embase, Web of Science Core Collection, WHO Global Index Medicus, PASCAL, Clinicaltrials.gov, Ovid Global Health, Cochrane Database and CENTRAL, and the WHO International Clinical Trials Registry Platform. Only prospective studies in humans with PKDL diagnosis, treatment, and follow-up measurements between January 1973 and March 2023 were included. Extracted data includes variables on patient characteristics, treatment regimens, diagnostic methods, geographical locations, efficacy endpoints, adverse events and statistical methodology. RESULTS: A total of 3,418 records were screened, of which 56 unique studies (n = 2,486 patients) were included in this review. Out of the 56 studies, 36 (64.3%) were from India (1983-2022), 12 (21.4%) from Sudan (1992-2021), 6 (10.7%) were from Bangladesh (1991-2019), and 2 (3.6%) from Nepal (2001-2007). Five (8.9%) studies were published between 1981-1990 (n = 193 patients), 10 (17.9%) between 1991-2000 (n = 230 patients), 10 (17.9%) between 2001-2010 (n = 198 patients), and 31 (55.4%) from 2011 onwards (n = 1,865 patients). Eight (14.3%) were randomised clinical trials, and 48 (85.7%) were non-randomised studies. The median post-treatment follow-up duration was 365 days (range: 90-540 days) in 8 RCTs and 360 days (range: 28-2,373 days) in 48 non-randomised studies. Disease diagnosis was based on clinical criterion in 3 (5.4%) studies, a mixture of clinical and parasitological methods in 47 (83.9%) and was unclear in 6 (10.7%) studies. Major drugs used for treatment were miltefosine (n = 636 patients), liposomal amphotericin B (L-AmB) (n = 508 patients), and antinomy regimens (n = 454 patients). Ten other drug regimens were tested in 270 patients with less than 60 patients per regimen. CONCLUSIONS: Our review identified studies with very limited sample size for the three major drugs (miltefosine, L-AmB, and pentavalent antimony), while the number of patients combined across studies suggest that the IPD platform would be valuable. With the support of relevant stakeholders, the global PKDL community and sufficient financing, a PKDL IPD platform can be realised. This will allow for exploration of different aspects of treatment safety and efficacy, which can potentially guide future healthcare decisions and clinical practices.


Subject(s)
Antiprotozoal Agents , Leishmaniasis, Cutaneous , Leishmaniasis, Visceral , Humans , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Cutaneous/drug therapy , Antiprotozoal Agents/therapeutic use , Observational Studies as Topic , Clinical Trials as Topic , Feasibility Studies , Treatment Outcome , India/epidemiology , Bangladesh/epidemiology
14.
Am J Trop Med Hyg ; 110(5): 910-920, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38574550

ABSTRACT

Surveillance for genetic markers of resistance can provide valuable information on the likely efficacy of antimalarials but needs to be targeted to ensure optimal use of resources. We conducted a systematic search and review of publications in seven databases to compile resistance marker data from studies in India. The sample collection from the studies identified from this search was conducted between 1994 and 2020, and these studies were published between 1994 and 2022. In all, Plasmodium falciparum Kelch13 (PfK13), P. falciparum dihydropteroate synthase, and P. falciparum dihydrofolate reductase (PfDHPS) genotype data from 2,953, 4,148, and 4,222 blood samples from patients with laboratory-confirmed malaria, respectively, were extracted from these publications and uploaded onto the WorldWide Antimalarial Resistance Network molecular surveyors. These data were fed into hierarchical geostatistical models to produce maps with a predicted prevalence of the PfK13 and PfDHPS markers, and of the associated uncertainty. Zones with a predicted PfDHPS 540E prevalence of >15% were identified in central, eastern, and northeastern India. The predicted prevalence of PfK13 mutants was nonzero at only a few locations, but were within or adjacent to the zones with >15% prevalence of PfDHPS 540E. There may be a greater probability of artesunate-sulfadoxine-pyrimethamine failures in these regions, but these predictions need confirmation. This work can be applied in India and elsewhere to help identify the treatments most likely to be effective for malaria elimination.


Subject(s)
Antimalarials , Artemisinins , Drug Combinations , Drug Resistance , Malaria, Falciparum , Plasmodium falciparum , Pyrimethamine , Sulfadoxine , Plasmodium falciparum/genetics , Plasmodium falciparum/drug effects , Pyrimethamine/therapeutic use , Pyrimethamine/pharmacology , Sulfadoxine/therapeutic use , Sulfadoxine/pharmacology , India/epidemiology , Drug Resistance/genetics , Antimalarials/therapeutic use , Antimalarials/pharmacology , Humans , Malaria, Falciparum/epidemiology , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , Artemisinins/therapeutic use , Artemisinins/pharmacology , Tetrahydrofolate Dehydrogenase/genetics , Genetic Markers , Dihydropteroate Synthase/genetics , Protozoan Proteins/genetics
15.
BMJ Glob Health ; 9(4)2024 04 22.
Article in English | MEDLINE | ID: mdl-38649182

ABSTRACT

BACKGROUND: The COVID-19 pandemic affected all WHO member states. We compared and contrasted the COVID-19 treatment guidelines of each member state with the WHO COVID-19 therapeutic guidelines. METHODS: Ministries of Health or accessed National Infectious Disease websites and other relevant bodies and experts were contacted to obtain national guidelines (NGs) for COVID-19 treatment. NGs were included only if they delineated specific pharmacological treatments for COVID-19, which were stratified by disease severity. We conducted a retrospective review using the adapted Reporting Checklist for Public Versions of Guidelines (RIGHT-PVG) survey checklist and a derived comparative metric based on the WHO guidelines was performed. RESULTS: COVID-19 therapeutics NGs could be obtained from 109 of the 194 WHO member states. There was considerable variation in guidelines and in disease severity stratifications. Therapeutic recommendations in many NGs differed substantially from the WHO guidelines. Overall in late 2022, 93% of NGs were recommending at least one treatment which had proved to be ineffective in large randomised trials, and was not recommended by WHO. Corticosteroids were not recommended in severe disease in nearly 10% of NGs despite overwhelming evidence of their benefit. NGs from countries with low-resource settings showed the greatest divergence when stratified by gross domestic product per year, Human Development Index and the Global Health Security Index. DISCUSSION: Our study is limited to NGs that were readily accessible, and it does not reflect the availability of recommended medicines in the field. Three years after the start of the SARS-CoV-2 pandemic, available COVID-19 NGs vary substantially in their therapeutic recommendations, often differ from the WHO guidelines, and commonly recommend ineffective, unaffordable or unavailable medicines.


Subject(s)
COVID-19 Drug Treatment , COVID-19 , Practice Guidelines as Topic , SARS-CoV-2 , World Health Organization , Humans , Retrospective Studies , Antiviral Agents/therapeutic use , Pandemics , Global Health
16.
Environ Pollut ; 351: 123962, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38614424

ABSTRACT

Polycyclic aromatic compounds (PACs) - a large group of organic chemicals naturally present in petroleum deposits (i.e., petrogenic) or released into the environment by incomplete combustion of organic materials (i.e., pyrogenic) - represent a potential risk to the health of aquatic ecosystems. In high latitude freshwater ecosystems, concentrations of PACs may be increasing, yet there are limited studies in such systems to assess change and to understand threats. Using 10 years of contemporary data from passive samplers deployed across five regions (n = 43 sites) in the Mackenzie River Basin, we (i) describe baseline levels of PACs, (ii) assess spatiotemporal patterns, and (iii) evaluate the extent to which environmental factors (fire, snowmelt, and proximity to oil infrastructure) influence concentrations in this system. Measured concentrations were low, relative to those in more southern systems, with mixtures primarily being dominated by non-alkylated, low molecular weight compounds. Concentrations were spatially consistent, except for two sites near Norman Wells (an area of active oil extraction) with increased levels. Similarly, observed annual variation was minimal, with 2014 having generally higher levels of PACs. We did not detect effects of fire, snowmelt, or oil infrastructure on concentrations. Taken together, our findings suggest that PACs in the Mackenzie River are currently at low levels and are primarily petrogenic in origin. They further indicate that ongoing monitoring and testing of environmental drivers (especially at finer spatial scales) are needed to better predict how ecosystem change will influence PAC levels in the basin and in other northern systems.


Subject(s)
Ecosystem , Environmental Monitoring , Polycyclic Aromatic Hydrocarbons , Water Pollutants, Chemical , Polycyclic Aromatic Hydrocarbons/analysis , Water Pollutants, Chemical/analysis , Rivers/chemistry , Fresh Water/chemistry
17.
Eur J Clin Invest ; 54(8): e14200, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38558254

ABSTRACT

BACKGROUND: Due to medical and surgical advancements, the population of adult patients with congenital heart disease (ACHD) is growing. Despite successful therapy, ACHD patients face structural sequalae, placing them at increased risk for heart failure and arrhythmias. Left and right ventricular function are important predictors for adverse clinical outcomes. In acquired heart disease it has been shown that echocardiographic deformation imaging is of superior prognostic value as compared to conventional parameters as ejection fraction. However, in adult congenital heart disease, the clinical significance of deformation imaging has not been systematically assessed and remains unclear. METHODS: According to the Preferred Reporting Items for Systematic Reviews checklist, this systematic review included studies that reported on the prognostic value of echocardiographic left and/or right ventricular strain by 2-dimensional speckle tracking for hard clinical end-points (death, heart failure hospitalization, arrhythmias) in the most frequent forms of adult congenital heart disease. RESULTS: In total, 19 contemporary studies were included. Current data shows that left ventricular and right ventricular global longitudinal strain (GLS) predict heart failure, transplantation, ventricular arrhythmias and mortality in patients with Ebstein's disease and tetralogy of Fallot, and that GLS of the systemic right ventricle predicts heart failure and mortality in patients post atrial switch operation or with a congenitally corrected transposition of the great arteries. CONCLUSIONS: Deformation imaging can potentially impact the clinical decision making in ACHD patients. Further studies are needed to establish disease-specific reference strain values and ranges of impaired strain that would indicate the need for medical or structural intervention.


Subject(s)
Echocardiography , Heart Defects, Congenital , Heart Failure , Humans , Heart Defects, Congenital/diagnostic imaging , Prognosis , Echocardiography/methods , Adult , Heart Failure/diagnostic imaging , Tetralogy of Fallot/diagnostic imaging , Tetralogy of Fallot/surgery , Ebstein Anomaly/diagnostic imaging , Ebstein Anomaly/physiopathology , Arrhythmias, Cardiac/diagnostic imaging , Heart Transplantation
18.
PLoS Comput Biol ; 20(4): e1012017, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38626207

ABSTRACT

Current malaria elimination targets must withstand a colossal challenge-resistance to the current gold standard antimalarial drug, namely artemisinin derivatives. If artemisinin resistance significantly expands to Africa or India, cases and malaria-related deaths are set to increase substantially. Spatial information on the changing levels of artemisinin resistance in Southeast Asia is therefore critical for health organisations to prioritise malaria control measures, but available data on artemisinin resistance are sparse. We use a comprehensive database from the WorldWide Antimalarial Resistance Network on the prevalence of non-synonymous mutations in the Kelch 13 (K13) gene, which are known to be associated with artemisinin resistance, and a Bayesian geostatistical model to produce spatio-temporal predictions of artemisinin resistance. Our maps of estimated prevalence show an expansion of the K13 mutation across the Greater Mekong Subregion from 2000 to 2022. Moreover, the period between 2010 and 2015 demonstrated the most spatial change across the region. Our model and maps provide important insights into the spatial and temporal trends of artemisinin resistance in a way that is not possible using data alone, thereby enabling improved spatial decision support systems on an unprecedented fine-scale spatial resolution. By predicting for the first time spatio-temporal patterns and extents of artemisinin resistance at the subcontinent level, this study provides critical information for supporting malaria elimination goals in Southeast Asia.


Subject(s)
Antimalarials , Artemisinins , Bayes Theorem , Drug Resistance , Artemisinins/pharmacology , Asia, Southeastern/epidemiology , Drug Resistance/genetics , Antimalarials/pharmacology , Humans , Spatio-Temporal Analysis , Plasmodium falciparum/drug effects , Plasmodium falciparum/genetics , Mutation , Malaria/drug therapy , Malaria/epidemiology , Computational Biology , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , Malaria, Falciparum/epidemiology
20.
Lancet Reg Health Southeast Asia ; 22: 100317, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38482151

ABSTRACT

Background: Occurrences of relapse after 6-months post-treatment has been reported in recent Visceral Leishmaniasis (VL) efficacy studies. A meta-analysis was carried out to quantify the proportion of relapses observed at and beyond 6-months using the Infectious Diseases Data Observatory (IDDO) systematic review (SR) database. Methods: Studies in the IDDO SR database (1983-2021; 160 studies) were eligible for inclusion if follow-up was at least 6-months, relapse was clearly reported, and patients with HIV coinfections were excluded. Meta-analysis of single proportion was undertaken and the estimates were reported with 95% confidence intervals (CI). Findings: Overall, 131 studies enrolling 27,687 patients were included; 1193 patients relapsed. In the Indian sub-continent (ISC), relapse estimates at 6-months was 4.5% [95% CI: 2.6%-7.5%; I2 = 66.2%] following single dose liposomal amphotericin B (L-AmB) and 1.5% [95% CI: 0.7%-3.3%; I2 = 0%] for L-AmB in a combination therapy. In East Africa (EA), corresponding estimates were 3.8% [95% CI: 1.3%-10.9%; I2 = 75.8%] following pentavalent antimony (PA), and 13.0% [95% CI: 4.3%-33.6%; I2 = 0%] for PA + paromomycin. From 21 studies with follow-up longer than 6-months, 0.6% [95% CI: 0.2%-1.8%; I2 = 0%] of patients relapsed after 6-months and estimated 27.6% [95% CI: 11.2%-53.4%; I2 = 12%] of relapses would have been missed by a 6-month follow-up. Interpretation: The estimated relapse proportion ranged from 0.5% to 4.5% in ISC and 3.8%-13.0% in EA with the currently recommended drugs. Over one-quarter of relapses would be missed with 6-months follow-up suggesting a longer follow-up may be warranted. Funding: Wellcome Trust (ref: 208378/Z/17/Z).

SELECTION OF CITATIONS
SEARCH DETAIL